CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore patent oppositions filed by Samsung Bioepis against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Aug 7, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of ComplementALEXION PHARMACEUTICALSMay 2, 2024
Safe And Effective Method Of Treating Ulcerative Colitis With Anti-Il12/Il23 AntibodyJANSSEN BIOTECHFeb 5, 2024
Methods And Compositions For Treating Complement-Associated DisordersALEXION PHARMACEUTICALSOct 4, 2023
Liquid Pharmaceutical CompositionFRESENIUS KABI DEUTSCHLANDOct 5, 2022
Liquid Pharmaceutical CompositionARES TRADINGApr 22, 2021
Liquid Pharmaceutical CompositionARES TRADINGJul 22, 2020
Pharmaceutical Anti-Tnf-Alpha Antibody FormulationRICHTER GEDEON NYRTDec 12, 2019
Pharmaceutical Anti-Tnf-Alpha Antibody FormulationRICHTER GEDEON NYRTJun 19, 2019
Liquid Pharmaceutical CompositionARES TRADINGMar 26, 2019

Explore Samsung Bioepis's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 7, 2025
Patent NumberGrant DateTitleTotal Oppositions
Apr 3, 2024Control Of Protein Glycosylation By Culture Medium Supplementation And Cell Culture Process Parameters1
Aug 10, 2022Methods For Overcoming Glutamine Deprivation During Mammalian Cell Culture1

Top competitors of Samsung Bioepis

List of top competitors of Samsung Bioepis based on patent oppositions.